ES2081823T3 - Agente para la aplicacion transdermica, que contiene gestoden. - Google Patents

Agente para la aplicacion transdermica, que contiene gestoden.

Info

Publication number
ES2081823T3
ES2081823T3 ES89118855T ES89118855T ES2081823T3 ES 2081823 T3 ES2081823 T3 ES 2081823T3 ES 89118855 T ES89118855 T ES 89118855T ES 89118855 T ES89118855 T ES 89118855T ES 2081823 T3 ES2081823 T3 ES 2081823T3
Authority
ES
Spain
Prior art keywords
agent
transdermal application
gestodene
containing gestodene
containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89118855T
Other languages
English (en)
Inventor
Clemens Gunther
Ulrich Dr Tauber
Karin Dr Schmidt-Gollwitzer
Jutta Dr Riedl
Johannes-Wilhelm Dr Tack
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DE19883836862 priority Critical patent/DE3836862A1/de
Priority to DE19893910578 priority patent/DE3910578A1/de
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Application granted granted Critical
Publication of ES2081823T3 publication Critical patent/ES2081823T3/es
Anticipated expiration legal-status Critical
Application status is Expired - Lifetime legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061Polyacrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches

Abstract

EL INVENTO DESCRIBE UN MEDIO PARA LA APLICACION TRANSDERMAL QUE SE CARACTERIZA YA QUE EL GESTODEN CONTIENE EN COMBINACION UNO O DOS OSTROGENOS.
ES89118855T 1988-10-27 1989-10-11 Agente para la aplicacion transdermica, que contiene gestoden. Expired - Lifetime ES2081823T3 (es)

Priority Applications (2)

Application Number Priority Date Filing Date Title
DE19883836862 DE3836862A1 (de) 1988-10-27 1988-10-27 Mittel zur transdermalen applikation von steroidhormonen
DE19893910578 DE3910578A1 (de) 1989-03-29 1989-03-29 Mittel zur transdermalen applikation enthaltend gestoden

Publications (1)

Publication Number Publication Date
ES2081823T3 true ES2081823T3 (es) 1996-03-16

Family

ID=25873728

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89118855T Expired - Lifetime ES2081823T3 (es) 1988-10-27 1989-10-11 Agente para la aplicacion transdermica, que contiene gestoden.

Country Status (20)

Country Link
US (1) US5788984A (es)
EP (3) EP0573133A1 (es)
JP (1) JP3238389B2 (es)
KR (1) KR0137463B1 (es)
CN (2) CN1036836C (es)
AT (1) AT132751T (es)
AU (3) AU4374789A (es)
CA (1) CA2001618C (es)
DE (1) DE58909570D1 (es)
DK (1) DK175804B1 (es)
ES (1) ES2081823T3 (es)
FI (1) FI100456B (es)
GR (1) GR3019079T3 (es)
HU (1) HU210549B (es)
IE (1) IE81077B1 (es)
IL (1) IL92007A (es)
MX (1) MX173621B (es)
NO (1) NO180567C (es)
PT (1) PT92131B (es)
WO (1) WO1990004397A1 (es)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991018570A1 (en) * 1990-06-01 1991-12-12 Robertson, Dale, N. Therapeutically effective topical application of st1435
US5198223A (en) * 1990-10-29 1993-03-30 Alza Corporation Transdermal formulations, methods and devices
US5320850A (en) * 1990-10-29 1994-06-14 Alza Corporation Transdermal delivery of the gestogen ST-1435 and devices therefor
CA2091883A1 (en) * 1990-10-29 1992-04-30 Robert M. Gale Transdermal contraceptive formulations, methods and devices
US5512292A (en) * 1990-10-29 1996-04-30 Alza Corporation Transdermal contraceptive formulations methods and devices
DE4210165A1 (de) * 1991-07-30 1993-02-04 Schering Ag Transdermale therapeutische systeme
AU665997B2 (en) * 1992-03-21 1996-01-25 Entec Gesellschaft Fur Endokrinologische Technologie M.B.H. Use of estriol for treating climacteric osteoporosis
JP2960832B2 (ja) * 1992-05-08 1999-10-12 ペルマテック テクノロジー アクチェンゲゼルシャフト エストラジオールの投与システム
DE4329242A1 (de) * 1993-08-26 1995-03-02 Schering Ag Mittel zur transdermalen Applikation enthaltend Gestodenester
JPH09510697A (ja) * 1994-01-27 1997-10-28 シエーリング アクチエンゲゼルシヤフト 14α,17α−エタノエストラ−1,3,5(10)−トリエン−3,17β−ジオールを含有する経皮投与のための薬剤
JPH0827003A (ja) * 1994-07-22 1996-01-30 Sekisui Chem Co Ltd 経皮吸収製剤
IL116539A (en) * 1995-01-06 2002-02-10 Noven Pharma Compositions for transdermal delivery of acid-labile drugs
US6024974A (en) * 1995-01-06 2000-02-15 Noven Pharmaceuticals, Inc. Composition and methods for transdermal delivery of acid labile drugs
IT1283102B1 (it) * 1996-06-06 1998-04-07 Permatec Nv Composizione terapeutica per la somministrazione transdermica di un principio attivo estrogeno o progestinico o di loro miscele
KR100215027B1 (ko) * 1997-01-27 1999-08-16 성재갑 스테로이드계 약물의 경피흡수투여용 조성물 및 이를 포함하는 경피흡수투여용 제형
DE19739916C2 (de) * 1997-09-11 2001-09-13 Hesch Rolf Dieter Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
IT1294748B1 (it) 1997-09-17 1999-04-12 Permatec Tech Ag Formulazione per un dispositivo transdermico
FR2772270B1 (fr) * 1997-12-15 2002-06-07 Besins Iscovesco Lab Utilisation d'un oestrogene pour le traitement de la depression postnatale
US6267984B1 (en) 1997-12-22 2001-07-31 Alza Corporation Skin permeation enhancer compositions comprising a monoglyceride and ethyl palmitate
DE10019171A1 (de) * 2000-04-07 2001-10-18 Schering Ag Zusammensetzungen zur Verwendung als Penetrationsverstärker in transdermalen Formulierungen für hoch lipophile Wirkstoffe
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20030139384A1 (en) * 2000-08-30 2003-07-24 Dudley Robert E. Method for treating erectile dysfunction and increasing libido in men
DE10107663B4 (de) * 2001-02-19 2004-09-09 Lts Lohmann Therapie-Systeme Ag Testosteronhaltiges transdermales therapeutisches System, Verfahren zu seiner Herstellung und seine Verwendung
FR2848112B1 (fr) * 2002-12-10 2007-02-16 Besins Int Belgique Composition pharmaceutique pour administration transdermique ou transmuqueuse comprenant au moins un progestatif et/ou au moins un oestrogene, son procede de preparation et ses utilisations
FR2851470B1 (fr) 2003-02-20 2007-11-16 Besins Int Belgique Composition pharmaceutique pour administration transdermique ou transmuqueuse
AT333271T (de) 2003-02-21 2006-08-15 Schering Ag Uv-stabiles transdermales pflaster
US7858607B2 (en) 2003-03-14 2010-12-28 Mamchur Stephen A System for use by compounding pharmacists to produce hormone replacement medicine customized for each consumer
US7879357B2 (en) 2003-04-28 2011-02-01 Bayer Schering Pharma Ag Pharmaceutical composition in the form of a hydrogel for transdermal administration of active ingredients
JO2492B1 (en) * 2003-04-28 2009-10-05 شيرينج ايه جي pharmaceutical composition in the form of a hydrogel for transdermal administration of active ingredients
US20050025833A1 (en) * 2003-07-16 2005-02-03 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
US20050020552A1 (en) * 2003-07-16 2005-01-27 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
US20050042268A1 (en) * 2003-07-16 2005-02-24 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
US20050037040A1 (en) * 2003-08-13 2005-02-17 Moshe Arkin Topical compositions of urea and ammonium lactate
US20050036953A1 (en) * 2003-08-13 2005-02-17 Moshe Arkin Topical compositions of ammonium lactate
US20050042182A1 (en) * 2003-08-13 2005-02-24 Moshe Arkin Topical compositions of urea
US20050129756A1 (en) * 2003-12-10 2005-06-16 Hans-Peter Podhaisky UV-stable, liquid or semisolid transdermal pharmaceutical preparation with light sensitive active ingredient
US8668925B2 (en) 2003-12-12 2014-03-11 Bayer Intellectual Property Gmbh Transdermal delivery of hormones without the need of penetration enhancers
CN1913878B (zh) * 2003-12-12 2010-05-26 拜耳先灵医药股份有限公司 无需渗透促进剂的激素透皮传递
JO2606B1 (en) 2003-12-12 2011-11-01 باير شيرنج فارما اكتنجيسيلشافت Transdermal Delivery of Hormones without the need of Penetration Enhancers
US7105263B2 (en) * 2003-12-30 2006-09-12 Samsung Electronics Company Dry toner comprising encapsulated pigment, methods and uses
US20050222106A1 (en) * 2004-04-01 2005-10-06 Stefan Bracht Drospirenone-containing preparations for transdermal use
GB0409498D0 (en) * 2004-04-28 2004-06-02 Hunter Fleming Ltd Transdermal steroid formulation
US20060008432A1 (en) * 2004-07-07 2006-01-12 Sebastiano Scarampi Gilsonite derived pharmaceutical delivery compositions and methods: nail applications
US8962013B2 (en) 2005-05-02 2015-02-24 Bayer Intellectual Property Gmbh Multi-layered transdermal system with triazine UV absorber
US20110086086A1 (en) * 2005-07-26 2011-04-14 Pfizer Inc Transdermal system for varenicline
DK2450041T3 (en) 2005-10-12 2018-11-19 Unimed Pharmaceuticals Llc Enhanced testosterone gel for use in the treatment of hypogonadism
DE102010040299A1 (de) 2010-09-06 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Transdermale therapeutische Systeme mit kristallisationsinhibierender Schutzfolie (Release Liner)
DK2613772T3 (en) 2010-09-06 2017-03-06 Bayer Ip Gmbh Transdermal low dosage patterns with high pharmaceutical release
MX2014006256A (es) 2011-11-23 2014-10-24 Therapeuticsmd Inc Formulaciones y terapias de reemplazo hormonal de combinacion naturales.
MX2014015900A (es) 2012-06-18 2015-07-17 Therapeuticsmd Inc Formulaciones de progesterona.
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150133421A1 (en) 2012-11-21 2015-05-14 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
MX2016014281A (es) 2014-05-22 2017-02-22 Therapeuticsmd Inc Formulaciones y terapias de reemplazo de combinación de hormonas naturales.
US20170216310A1 (en) 2014-10-22 2017-08-03 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3333240A1 (de) * 1983-09-12 1985-03-28 Schering Ag Mittel zur transdermalen applikation von arzneimittelwirkstoffen
FI83087C (fi) 1984-05-16 1991-05-27 Schering Ag Foerfarande foer framstaellning av terapeutiskt anvaendbara estriol-3,17-diestrar.
EP0186019B1 (de) * 1984-12-22 1993-10-06 Schwarz Pharma Ag Wirkstoffpflaster
DE3511587A1 (de) * 1985-03-27 1986-10-02 Schering Ag Glykoester des estradiols und estriols
CN1021196C (zh) * 1986-12-29 1993-06-16 新泽西州州立大学(鲁杰斯) 透皮雌激素/孕激素药剂单元、系统及方法
US4788062A (en) * 1987-02-26 1988-11-29 Alza Corporation Transdermal administration of progesterone, estradiol esters, and mixtures thereof
CH674618A5 (es) * 1987-04-02 1990-06-29 Ciba Geigy Ag
US5422119A (en) * 1987-09-24 1995-06-06 Jencap Research Ltd. Transdermal hormone replacement therapy
FR2717689B1 (fr) * 1994-03-28 1996-07-05 Lhd Lab Hygiene Dietetique Système matriciel transdermique d'administration d'un oestrogène et/ou un progestatif à base de copolymère styrène-isoprène-styrène.
FR2717688B1 (fr) * 1994-03-28 1996-07-05 Lhd Lab Hygiene Dietetique Système matriciel transdermique d'administration d'un oestrogène et/ou un progestatif à base d'EVA.

Also Published As

Publication number Publication date
CN1069829C (zh) 2001-08-22
AT132751T (de) 1996-01-15
JP3238389B2 (ja) 2001-12-10
DK138590A (da) 1990-06-06
HU896546D0 (en) 1990-12-28
FI100456B1 (es)
IL92007A (en) 1995-12-08
DE58909570D1 (de) 1996-02-22
IE893376L (en) 1990-04-27
FI903213A0 (fi) 1990-06-26
EP0394429B1 (de) 1996-01-10
EP0370220A1 (de) 1990-05-30
GR3019079T3 (en) 1996-05-31
IL92007D0 (en) 1990-07-12
CN1042075A (zh) 1990-05-16
NO180567C (no) 1997-05-14
AU4374789A (en) 1990-05-03
MX173621B (es) 1994-03-18
CN1036836C (zh) 1997-12-31
NO180567B (no) 1997-02-03
HU210549B (en) 1995-05-29
FI903213D0 (es)
PT92131B (pt) 1995-06-30
CA2001618C (en) 2000-06-20
IE81077B1 (en) 2000-02-23
CA2001618A1 (en) 1990-04-27
EP0573133A1 (de) 1993-12-08
NO902840L (no) 1990-06-26
FI100456B (fi) 1997-12-15
EP0394429A1 (de) 1990-10-31
JPH03502700A (es) 1991-06-20
PT92131A (pt) 1990-04-30
KR0137463B1 (ko) 1998-06-01
WO1990004397A1 (de) 1990-05-03
AU2059695A (en) 1995-08-31
EP0370220B1 (de) 1996-01-10
US5788984A (en) 1998-08-04
DK175804B1 (da) 2005-03-07
DK138590D0 (da) 1990-06-06
NO902840D0 (no) 1990-06-26
KR900005969A (ko) 1990-05-07
CN1157719A (zh) 1997-08-27
AU3001192A (en) 1993-02-11

Similar Documents

Publication Publication Date Title
ES2058061T3 (es) Derivado de piperidina, su preparacion y su uso como medicamento.
BR0106967A (pt) Dispositivo de acondicionamento e/ou de aplicação que contém fibras que possuem pelo menos um corpo imantado ou imantável
DK0380063T3 (da) 1,2-Cyclohexylaminoarylamider til anvendelse som analgetika
DE69316210D1 (de) Fehlerbeseitiger, der die zuordnung zwischen dem quellprogramm und optimierten objektcode beinhaltet.
ES2086503T3 (es) Composiciones de concentrado liquido de edulcorante.
DE69015886D1 (de) Fotochromische Verbindung, deren Zusammensetzung und Verwendung.
NO945036D0 (no) Vandig materiale som inneholder en organisk peroksysyre
ES269154Y (es) Dispositivo introductor para cateteres, sondas o elementos similares.
ES2148308T3 (es) Contenido de aceite modificado en semillas.
UY25157A1 (es) Composiciones farmacéuticas conteniendo atorvastatina y amlodipino
ES2159604T3 (es) Selladores y adhesivos de poliuretano que contienen polioles de hidrocarburos saturados.
ES2015879B3 (es) Un articulo absorbente que tiene ribetes dobles.
AT160693T (de) Spritze zum dosierten abgeben von viskosen werkstoffen, insbesondere von dentalen werkstoffen
NO953093D0 (no) Forbindelser med både sterk kalsiumantagonist- og antioksidantvirkning, samt anvendelse derav som cellebeskyttende midler
DE3876368D1 (de) Haertbare polysiloxanzusammensetzung.
NO971192D0 (no) Fremgangsmåter for avlevering av materialer inn i huden, og sammensetninger som blir anvendt
MX9205069A (es) Composiciones de revestimiento novedosas que se pueden curar en el ambiente.
IT8019175D0 (it) Elettrorivestimento. composizione di resina per
ES2114183T3 (es) Anticuerpo para el tratamiento de la diabetes dependiente de la insulina.
AR034709A1 (es) Un procedimiento para la telomerizacion de olefinas aciclicas.
DK0698393T3 (da) 3-/-menthoxypropan-1,2-diol som solubiliseringsmiddel og præparat til udvortes brug, der indeholder samme
SV1995000045A (es) Benzoxazolil- y benzotiazoliloxazolidinonas, ref. le a 30616-sv
FR2705566B1 (fr) Nouvelles compositions pharmaceutiques.
NL184364C (nl) Carbostyrilderivaten en zouten daarvan, alsmede gevormd farmaceutisch preparaat dat een of meer van dergelijke carbostyrilverbindingen bevat.
AR020021A1 (es) Composicion para el tratamiento de cancer usando aceites esenciales de plantas naturales con moduladores de transduccion de senal

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 370220

Country of ref document: ES